GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Total Liabilities

StemRIM (TSE:4599) Total Liabilities : 円243 Mil (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM Total Liabilities?

StemRIM's Total Liabilities for the quarter that ended in Jan. 2024 was 円243 Mil.

StemRIM's quarterly Total Liabilities declined from Jul. 2023 (円336.02 Mil) to Oct. 2023 (円237.28 Mil) but then increased from Oct. 2023 (円237.28 Mil) to Jan. 2024 (円242.67 Mil).

StemRIM's annual Total Liabilities declined from Jul. 2021 (円212.64 Mil) to Jul. 2022 (円192.43 Mil) but then increased from Jul. 2022 (円192.43 Mil) to Jul. 2023 (円336.02 Mil).


StemRIM Total Liabilities Historical Data

The historical data trend for StemRIM's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Total Liabilities Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Total Liabilities
Get a 7-Day Free Trial 91.96 431.36 212.64 192.43 336.02

StemRIM Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 211.16 372.65 336.02 237.28 242.67

StemRIM Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

StemRIM's Total Liabilities for the fiscal year that ended in Jul. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=217.554+(0+118.47
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=336

Total Liabilities=Total Assets (A: Jul. 2023 )-Total Equity (A: Jul. 2023 )
=10706.482-10370.458
=336

StemRIM's Total Liabilities for the quarter that ended in Jan. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=124.116+(0+118.555
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=243

Total Liabilities=Total Assets (Q: Jan. 2024 )-Total Equity (Q: Jan. 2024 )
=10060.174-9817.503
=243

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM Total Liabilities Related Terms

Thank you for viewing the detailed overview of StemRIM's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM (TSE:4599) Business Description

Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM (TSE:4599) Headlines

No Headlines